Welcome to our dedicated page for SCOPUS BIOPHARMA news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on SCOPUS BIOPHARMA stock.
Scopus Biopharma Inc. (SCPS) is a biopharmaceutical company focused on developing novel therapeutic candidates to treat serious diseases with significant unmet medical needs. The company engages in the discovery, development, and commercialization of innovative medicines. Scopus Biopharma's core business involves leveraging proprietary technologies and collaborating with academic institutions to advance its product pipeline.
Scopus Biopharma has a diverse portfolio of drug candidates, including immuno-oncology treatments, antiviral therapies, and regenerative medicines. One of their leading projects is the development of a small molecule that targets certain genetic markers associated with various cancers, which has shown promising preclinical results.
The company has established strategic partnerships with leading research institutions and biotech firms to enhance its R&D capabilities and accelerate the clinical development of its therapeutics. Scopus Biopharma's financial health is bolstered by successful funding rounds and a strong commitment to maintaining a robust balance sheet.
Recent achievements include the initiation of early-stage clinical trials for their lead cancer treatment candidate and collaborations aimed at expanding their research into new therapeutic areas. These milestones signify the company's dedication to bringing groundbreaking treatments to market.
Investors and stakeholders can look forward to continuous updates on Scopus Biopharma's progress, as the company remains at the forefront of biopharmaceutical innovation. The ongoing commitment to addressing critical health challenges underscores the importance of Scopus Biopharma in the biotech landscape.
Scopus BioPharma (Nasdaq: SCPS) announced the presentation of key scientific data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston, Massachusetts. The company, dedicated to developing transformational therapeutics for unmet medical needs, operates through its immuno-oncology subsidiary, Duet BioTherapeutics. Launched in September 2021, Duet focuses on innovative immunotherapy assets, including three CpG-STAT3 inhibitors. The press release also includes a disclaimer regarding forward-looking statements and associated risks.
Scopus BioPharma (Nasdaq: SCPS) announced the completion of recapitalization transactions aimed at enhancing shareholder value. This includes eliminating warrants for approximately 21 million shares and valuing its subsidiary, Duet BioTherapeutics, at $25 million, which Scopus owns about 90%. The recapitalization is expected to act as a catalyst for increasing Scopus' stock price. Duet is positioned to raise capital and go public in 2023, significantly advancing its proprietary antisense technology and research initiatives.
Scopus BioPharma Inc. (Nasdaq: SCPS) has appointed Raphael Hofstein, Ph.D. to its Board of Directors, bringing extensive experience in biotechnology. Hofstein has co-founded over 60 biopharma companies and is currently Chairman of Fibrocor Therapeutics. His insights are expected to enhance the company's Duet Platform, which targets the challenging protein STAT3, utilizing innovative nucleic acid-based molecules. This appointment follows recent board changes due to a contested election. Investors remain cautious due to ongoing legal challenges regarding the election results.
Scopus BioPharma (Nasdaq: SCPS) announced that Dr. Alan Horsager, CEO of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting Therapies Summit from March 22-24, 2022. His presentation titled TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology will focus on novel methods of targeting immune pathways. The Duet Platform, launched in September 2021, integrates immunotherapy assets and includes three distinct CpG-STAT3 inhibitors: DUET-01, DUET-02, and DUET-03. These inhibitors aim to enhance immune responses against tumors.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the results of its Annual Meeting, revealing that over 90% of shares voted by unaffiliated stockholders supported the re-election of directors. However, the voting results are being challenged in court by directors against Morris C. Laster, who claims to own 6,000,000 shares. Legal actions may impact the ultimate outcome of the meeting.
The company emphasizes its commitment to protect legitimate shareholder interests against potential misconduct by the Lasters. Scopus is focused on developing innovative therapies for serious diseases.
On January 6, 2022, Dr. Morris C. Laster announced the successful election of his nominees, Mordechai Saar Hacham and Joshua Levine, to the Board of Directors of Scopus BioPharma (Nasdaq: SCPS). The announcement followed the Company's 2021 Annual Meeting, where Hacham and Levine received 8,276,505 and 8,276,338 votes, respectively, defeating the incumbent nominees. Additionally, stockholders voted against the ratification of Citrin Cooperman & Company as the Company's independent accounting firm. Dr. Laster emphasized that this outcome reflects stockholder desires for more independent stewardship.
Scopus BioPharma (Nasdaq: SCPS) has issued a second letter to stockholders ahead of its Annual Meeting on December 20, urging them to vote “FOR ALL” director nominees on the WHITE proxy card. The company highlights concerns about Morris C. Laster’s ongoing campaign for board control, which it claims has destroyed over $100 million in shareholder value this year. The stock price has fallen from $10 to below $2, despite the company's advancements in regulatory milestones and asset acquisition. Scopus asserts that Laster's motives are self-serving and calls for unity among shareholders.
Scopus BioPharma Inc. (Nasdaq: SCPS) is urging stockholders to support its director nominees, Dr. Raphael Hofstein and Dr. David S. Battleman, in the upcoming reconvened Annual Meeting on December 20, 2021. The company has raised $9.75 million in non-dilutive financing, fully absorbed by its Executive Committee's contribution of warrants to purchase six million shares. Scopus emphasizes its commitment to developing transformational therapeutics for cancer treatment, leveraging groundbreaking scientific advances and achieving key developmental milestones between now and early 2023.
FAQ
What is the current stock price of SCOPUS BIOPHARMA (SCPS)?
What is the market cap of SCOPUS BIOPHARMA (SCPS)?
What does Scopus Biopharma Inc. do?
What are some of the company’s core products?
What are some recent achievements of Scopus Biopharma?
Who are Scopus Biopharma’s partners?
What is the financial condition of Scopus Biopharma?
What type of diseases does Scopus Biopharma target?
Why is Scopus Biopharma significant in the biotech landscape?
How does Scopus Biopharma advance its pipeline?
What is the company’s approach to research and development?
Where can I find updates on Scopus Biopharma’s progress?
